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Abstract
Neurodegenerative diseases ranging from Alzheimer disease and polyglutamine diseases to 
transmissible spongiform encephalopathies are associated with the aggregation and accumulation 
of misfolded proteins. In several cases the intracellular and extracellular protein deposits contain a 
fibrillar protein species called amyloid. However while amyloid deposits are hallmarks of 
numerous neurodegenerative diseases, their actual role in disease progression remains unclear. 
Especially perplexing is the often poor correlation between these deposits and other markers of 
neurodegeneration. As a result the question remains whether amyloid deposits are the disease-
causing species, the consequence of cellular disease pathology or even the result of a protective 
cellular response to misfolded protein species. Here we highlight studies that suggest that 
accumulation and sequestration of misfolded protein in amyloid inclusion bodies and plaques can 
serve a protective function. Furthermore, we discuss how exceeding the cellular capacity for 
protective deposition of misfolded proteins may contribute to the formation of toxic protein 
species.
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Introduction
The study of neurodegenerative diseases began over a hundred years ago when Alois 
Alzheimer identified fibrillar structures within the postmortem brain of a patient who had 
exhibited progressive cognitive dysfunction and psychosis.1 It is now known that the 
majority of neurodegenerative diseases characterized by progressive neuronal dysfunction 
and loss are associated with the deposition of misfolded proteins. These misfolded proteins 
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are frequently found in a β-sheet-rich fibrillar protein conformation known as amyloid2,3 
(Fig. 1). For more than forty years amyloid deposits were thought to be causative agents in 
the degenerative process.4 But the tables have turned. Recent studies suggest instead that a 
group of still poorly defined pre-amyloid species, rather than the amyloid deposits 
themselves, are the true toxic conformations5–8 (Fig. 1). These soluble prefibrillar oligomers 
share conformational characteristics independent of the proteins’ primary amino acid 
sequences and may share a common mechanism of toxicity.5 Indeed even proteins 
completely unrelated to disease, such as PI3 kinase and the E. Coli protein HypF-N, can be 
induced to form such prefibrillar structures in vitro and, when they do, they are toxic when 
applied extracellularly to cells in culture or injected into rat brains.9,10 The intra- and 
extracellular conversion of misfolded proteins into highly structured and less reactive 
amyloid forms may reduce the levels of these toxic protein species and therefore be 
protective.
For the purpose of this perspective, we focus on three neuro-degenerative diseases, 
Alzheimer disease, Huntington disease and prion disease. We will first present studies in 
which the formation of inclusion bodies and amyloid plaques protects against proteo-toxicity 
and then discuss how exceeding the cellular capacity for deposition of misfolded proteins 
may give rise to toxic protein species. Although these studies do not preclude detrimental 
effects of amyloid deposits in particular contexts (e.g., obstructive vascular amyloid), they 
clearly show that amyloid formation can be beneficial.
Pathological Features Associated with Neurodegenerative Diseases
The protein deposits found in Alzheimer disease, Huntington disease and prion disease are 
formed by completely unrelated proteins. They accumulate in distinct brain regions and have 
highly characteristic morphologies that form the basis of histological diagnosis. 
Neurodegeneration also affects distinct regions of the brain in each disease, reflecting a 
disease-specific vulnerability of particular neurons.11 However, in all three diseases the 
correlation between the localization of neurodegeneration and protein deposition is weak.
Alzheimer disease
Alzheimer disease (AD), the most common cause of dementia, most severely affects the 
temporal pole, hippocampus and amygdala.12 AD is characterized by the accumulation of 
two very different proteins, each with a distinct distribution. Aβ (amyloid β) peptide 
accumulates extracellularly in amyloid plaques while hyperphosphorylated tau, a 
microtubule binding protein, accumulates intracellularly in neurofibrillary tangles. A 
definitive pathological diagnosis of AD requires the detection of both types of aggregation. 
Aβ may accumulate in different plaque forms. Neuritic plaques, also referred to as classic or 
cored plaques, contain a dense amyloid core surrounded in turn by a ring of abnormal 
cellular processes and a rim of diffuse amyloid.11,12 In these neuritic plaques tau 
accumulation can also be present in dystrophic neurites surrounding the amyloid core.
It has been hypothesized that Aβ accumulation is the primary cause of pathogenesis in AD, 
yet there is a weak correlation between Aβ plaque density and the severity of dementia.11 
For example, brain samples of aged patients without clinical dementia can display abundant 
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Aβ plaques.11 To some extent this may be the consequence of Aβ accumulating in plaques 
without any associated neuritic degeneration (such as “burned-out” and “diffuse plaques”). 
Tau-containing neurofibrillary tangles correlate better with clinical severity of AD than Aβ 
plaques, but even here, the question remains whether tau aggregation itself is toxic or if it is 
the result of a protective mechanism.13–16
Huntington disease
Huntington disease (HD), classified as a hyperkinetic movement disorder, tends to affect 
brain regions distinct from those affected by Alzheimer disease. HD is characterized by 
atrophy of the cerebral cortex, globus pallidus and striatum, specifically the loss of medium 
spiny neurons within the neostriatum.17–19 HD is caused by CAG repeat expansions in the 
huntingtin gene, which lead to the accumulation of polyglutamine-expanded huntingtin 
protein within intranuclear inclusion bodies or neurites.11 The density of intranuclear 
inclusions correlates positively with the CAG repeat length present in the huntingtin gene.20 
However, neuronal vulnerability does not correspond to the cellular concentration of 
huntingtin protein nor the distribution of huntingtin inclusions.21 In fact there is a distinct 
dissociation of inclusion distribution and the selective pattern of striatal neuron loss, as few 
to no inclusions are detected in the vulnerable striatal neurons.22
Prion diseases or spongiform encephalopathies
Prion diseases or spongiform encephalopathies can present in numerous ways, such as the 
sporadic versus variant forms of Creutzfeldt-Jakob disease (CJD). While the prion disease 
subtypes all involve the accumulation of a proteinase-K resistant form of the prion protein 
PrP (PrPres), they each affect different brain regions and involve distinct patterns of PrP 
aggregation.11 Sporadic CJD causes spongiform change in the neuropil of the cerebral 
cortex, subcortical grey matter and cerebellar molecular layer.23 The brainstem and spinal 
cord do not exhibit spongiform change although PrP deposits can be present. PrPres deposits 
in sporadic CJD are found in synaptic, perivacuolar, perineuronal and plaque-like patterns.23 
Neuronal loss correlates with microglial activation and axonal damage, but not with local 
deposition of PrPres. In contrast, variant CJD, caused by the consumption of meat from 
cows with Bovine Spongiform Encephalopathy, leads to the presence of a large number of 
florid plaques in the cerbral and cerebellar cortex.24 Florid plaques have a dense amyloid 
core, a pale radiating fibrillar periphery and are surrounded by a halo of spongiform change. 
Interestingly, spongiform change in variant CJD is most pronounced in the basal ganglia, 
which contain relatively few amyloid plaques.24
In summary, while the particular misfolded proteins vary in these diseases, in all three cases 
protein deposits are a poor indicator of neuronal loss. This makes it plausible that structured 
protein deposits help cells to cope with misfolded proteins. In turn, the failure of particular 
neurons to create such deposits may cause their disease-specific vulnerability.
Protein Deposition as a Cellular Response to Misfolded Proteins
One of the first indications that protein inclusions may protect cells from toxic misfolded 
proteins came from a study investigating the response of tissue culture cells to either 
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proteasome inhibitors or to overexpression of proteins targeted to the proteasome. The 
Kopito laboratory established that exceeding the proteasome’s capacity to cope with 
misfolded proteins, by either perturbation, leads to the accumulation of stable aggregates at a 
distinct structure adjacent to the centrosome.25 This structure was termed the aggresome to 
emphasize that its formation is a common cellular response to the presence of aggregated 
misfolded protein.
The aggresome is a highly structured deposit of insoluble protein surrounded by a cage 
formed by the intermediate filament protein vimentin. Most strikingly, aggresomes are 
formed near the centrosome through dynein-dependent retrograde transport of protein 
aggregates along microtubules.25–27 Far from being amorphous protein accumulations, 
aggresomes are formed through an active and conserved cellular process, that appears to 
serve a vital purpose: sweeping the cytoplasm clear of potentially toxic forms of misfolded 
proteins.28
Protein Deposition as a Protective Mechanism
A host of studies involving proteins linked to neurodegenerative diseases and other 
amyloidogenic proteins have investigated the role of inclusion and plaque formation in 
pathogenicity. The case is perhaps strongest for Huntington disease, for which it has been 
postulated that inclusions cause toxicity due to the sequestration of proteins critical for cell 
homeostasis.29 Inclusions formed by mutant huntingtin protein have been shown to 
sequester glycer-aldehyde-3-phosphate dehydrogenase, to impair transcription due to 
sequestration of the transcriptional coactivator CREB binding protein, and to interfere with 
the function of the ubiquitin-proteasome system.30–32 However smaller oligomeric species 
and loosely packed amorphous aggregates may be more prone to interact with and sequester 
proteins than densely packed amyloid deposits.
Indeed, several studies suggest that the formation of tightly packed huntingtin deposits is 
beneficial for cell survival. The Greenberg laboratory transfected with mutant huntingtin 
primary striatal neuron to induce the formation of inclusions.33 The inclusions formed 
resembled protein deposits found in the brains of Huntington patients, as they were 
intranuclear and ubiquitinylated. But these inclusions were not sufficient to induce 
apoptosis. On the contrary, inhibition of the ubiquitinylation of mutant Huntingtin prevented 
the formation of inclusions and actually increased cell death.33
In a complementary study, the Finkbeiner group used time-lapse microscopy to follow the 
fate of individual huntingtin transfected neurons. The majority of neurons died without the 
formation of inclusion bodies and the formation of an inclusion body actually increased the 
probability of neuron survival.34 The formation of inclusion bodies directly correlated with a 
decrease in soluble huntingtin, suggesting that inclusion bodies protect neurons by 
decreasing levels of soluble toxic isoforms of huntingtin.34 Inclusion body formation may 
also serve a protective function by increasing the autophagic degradation of the aggregated 
protein species.35 Inclusions of mutant huntingtin directly induce autophagy through 
sequestration of mTOR, a negative regulator of autophagy, and autophagy not only reduces 
the levels of aggregated but also soluble mutant huntingtin.36,37
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Together, these studies suggest that compounds elevating the formation of inclusion bodies, 
such as aggresomes, could lessen cellular pathology. On the other hand compounds that 
antagonize the toxicity of mutant huntingtin by reducing its aggregation have been 
identified.38 On the surface, this appears to conflict with the notion that promoting 
inclusions may be beneficial, but both, solubilization and inclusion body formation, may 
diminish the levels of toxic oligomers, the more critical species in pathogenesis. In fact, in 
one HD model a compound prevented huntingtin-mediated proteasome dysfunction by 
promoting inclusion formation.39
Although the characteristic protein deposits are found extracellularly in AD and prion 
disease, not intracellularly as in HD, here too studies suggest that structured protein deposits 
are less toxic than other conformers. As for HD, amyloid assembly may serve a beneficial 
function by shifting the equilibrium away from more toxic conformers, such as prefibrillar 
oligomers.5,6,8
In a collaborative effort, the Kelly and Dillin laboratories investigated the roles of the aging 
process and the heat shock response in the formation of proteotoxic species in a 
Caenorhabiditis elegans model of AD. The intracellular expression of Aβ resulted in the 
formation of Aβ aggregates, but these aggregates did not correlate with toxicity.40 RNAi-
mediated repression of the insulin/IGF-1 receptor DAF-2, resulting in increased life span, 
reduced Aβ-mediated toxicity while slightly increasing the amount of Aβ aggregates. This 
protection depended on both daf-16 and hsf-1. Interestingly, repression of DAF-16 reduced 
the number of high molecular weight Aβ aggregates, while repression of HSF-1 increased it. 
The Kelly and Dillin laboratories concluded that two dichotomous cellular pathways 
counteract Aβ toxicity: The HSF-1 pathway controls disaggregation, while the DAF-16 
pathway transforms toxic Aβ oligomers into larger Aβ aggregates of lower toxicity.40
In a separate study by the Mucke group, a point mutation within Aβ, the Arctic mutation (Aβ 
E22G), influenced the rate at which Aβ assembled into amyloid fibers. In vitro and in 
transgenic mice, the Artic mutation enhanced formation of neuritic amyloid plaques and 
diminished non-amyloid Aβ assemblies.41 As non-amyloid Aβ assemblies correlated with 
behavioral and neuronal deficits in these transgenic mice, the promotion of Aβ amyloid fibril 
formation, without a coinciding increase in oligomeric Aβ, may be beneficial.
Most recently, in a follow-up study of a clinical trial, immunization of AD patients with the 
full length Aβ peptide reduced Aβ immunostaining and amyloid plaques.42 Unfortunately, 
immunization neither slowed nor stopped the progression of neurodegeneration. As 
immunization with Aβ peptide may not have reduced the levels of toxic oligomeric Aβ 
species, the authors suggest, that immunization specifically against oligomeric Aβ species 
may be more successful at halting neurodegeneration.
Plaque formation may also prove beneficial in the case of prion disease. PrPres isoforms, the 
protease resistant forms of PrP that include amyloid, are not toxic on their own. Mice that do 
not express their own PrP protein (Prn-p0/0) are completely resistant to intracerebral 
injection of even very high doses of PrPres.43 Equally striking, mice producing a secreted 
form of PrP, GPI anchor-less PrP, accumulated massive plaque-like amyloid deposits, yet 
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had no clinical manifestations of prion disease.44 Some brain lesions were present, but less 
neurodegeneration was associated with these amyloid plaques than with diffuse wild type 
PrPres deposits. These results were especially significant as transgenic mice had up to 40% 
more PrPres than mice with WT PrP.44 Using human tissue samples, the Barron laboratory 
showed that the accumulation of certain forms of PrPres fails to result in spongiform 
degeneration.45 Brain extracts from two cases of familial prion disease were used to test the 
transmission of disease to transgenic mice. One of the samples exhibited PrPres deposits and 
spongiform change, while the other presented with PrPres deposits and no spongiform 
change. Brain extract from the patient without spongiform degeneration did not result in 
disease transmission but elicited PrPres deposition in large multicentric plaques. Therefore, 
PrPres would appear to be rendered nonpathogenic by its sequestration in amyloid 
plaques.45
Lessons from a Yeast Model
Yeast prion proteins, just as PrP, can adopt self-perpetuating conformational states. In yeast, 
however, prions do not cause disease, but rather serve as heritable genetic elements, 
perpetuated by the transfer of the prion template from mother to daughter cells.46 The 
heritable protein conformation of the yeast prions is amyloid in nature and, as for Aβ, 
Huntingtin and PrP, amyloid formation by the yeast prion proteins proceeds through 
intermediate oligomeric protein species.47,48 In fact, the observation that prefibrillar 
oligomers are intermediates in amyloid formation was first made for the yeast prion protein 
Sup35.47,49 Oligomers formed by the yeast prion protein Sup35 share structural features 
with the oligomers formed by disease-related amyloidogenic proteins, including recognition 
by anti-oligomeric antibodies and interaction with specific small compounds.49,50 Thus the 
study of yeast prions can provide insight into amyloid formation and cellular responses to 
the presence of amyloid.
The yeast prion [RNQ+] is formed by the Rnq1 protein (The cytoplasmic inheritance of 
yeast prions is designated by [ ]). Rnq is nonessential and has no known biological function, 
except when it is in the prion state.51 The [RNQ+] prion interacts with other amyloidogenic 
proteins in vivo and enables them to adopt their amyloid conformation. For example, 
[RNQ+] facilitates the de novo induction of the [PSI+] prion state by enhancing the amyloid 
conversion of the yeast prion protein Sup35.52
We recently reported that moderate ectopic overexpression of Rnq1 is extremely toxic if 
endogenous Rnq1 is in the [RNQ+] prion conformation.53 While overexpression of Rnq1 did 
result in the formation of amyloid inclusions, as assessed by Thioflavin-T staining, semi-
denaturing agarose gels and in vitro seeding assays, the amyloid conformation did not 
represent the toxic species. In fact, co-expression of an Hsp40 chaperone, Sis1, known to 
interact with the prion form of Rnq1,54 suppressed the toxicity elicited by Rnq1 
overexpression by promoting Rnq1 assembly into amyloid. Mutants of Rnq1, impaired in 
their interaction with the chaperone and their ability to readily form amyloid, exhibited 
enhanced toxicity. Chaperones have been shown to antagonize toxicity associated with 
protein misfolding before, but in those cases overexpressed chaperones either decreased 
protein aggregation55 or appeared to have no observable effect on protein aggregation.56 
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Our study presents the first instance in which a chaperone antagonizes the toxicity of a 
misfolding protein by facilitating its deposition into an amyloid inclusion. It clearly 
demonstrates that actively promoting the formation of inclusion bodies and even amyloid 
plaques may prove beneficial in protein misfolding pathologies.
Formation of Toxic Protein Species Due to Non-Productive Templating
While the formation of aggresomes and extracellular amyloid plaques appears to serve a 
protective function, they could be associated with toxicity if their assembly is overwhelmed 
by the amount of protein damage or impeded by other molecular and cellular factors. As 
shown by the Kampinga group, aggresome formation by mutant huntingtin in tissue culture 
cells did not affect the cellular progression through mitosis. However, when the mutant 
huntingtin formed scattered secondary inclusions, the completion of mitosis was delayed or 
even failed completely.57 The Kampinga group speculated that these secondary inclusions, 
distinct from aggresomes, form when the process of aggresome formation is saturated. 
These results are reminiscent of our studies in which overexpression of the yeast prion 
protein Rnq1 resulted in toxicity when it exceeded the cellular capacity to efficiently 
assemble the prion protein into amyloid. The toxicity of Rnq1 overexpression was 
exacerbated by factors interfering with amyloid assembly, such as repression of Sis1, the 
chaperone required for Rnq1 amyloid formation, or mutations within Rnq1, which reduce its 
interaction with the chaperone.53
Importantly, Rnq1 overexpression only resulted in toxicity if the endogenous Rnq1 protein 
was in its [RNQ+] prion conformation, making the otherwise benign prion state a 
prerequisite for Rnq1 mediated toxicity. Interestingly, the Rnq1 prion state is also required 
for toxicity of mutant huntingtin exon 1 in yeast models of Huntington disease.58 While the 
Rnq1 prion conformation usually acts as a template for the conversion of soluble Rnq1 
protein into benign amyloid conformers, we hypothesize that this process can also result in 
the formation of toxic protein species. We refer to this as non-productive templating, which 
occurs when the cellular capacity to facilitate amyloid formation is exceeded or impeded 
(Fig. 2).
The notion of non-productive templating offers a unifying explanation for the observation 
that the presence of amyloid formation is sometimes associated with toxicity even when the 
amyloid form itself is benign. We discuss two cases in point: As mentioned earlier, the 
expression of GPI-anchorless PrP resulted in the formation of amyloid plaques but was not 
overtly toxic. However, when GPI-anchorless PrP was expressed together with WT PrP, 
deposits of both amyloid and non-amyloid PrPres formed and the clinical manifestations of 
prion disease were enhanced.44 Furthermore, it has been suggested that PrPres subverts a 
stress protective function of PrP into an apoptotic signal.59 The toxic signal elicited is 
dependent on the presence of PrPres and the expression of GPI-anchored PrP.59 PrPres may 
influence the folding state of the GPI-anchored PrP through incomplete templating and thus 
cause the induction of a toxic signal.
The second case in point involves the fungal prion [Het-s]. Non-productive templating may 
explain how the [Het-s] prion mediates heterokaryon incompatibility in the fungus 
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Podospora anserina.60 Heterokaryon incompatability, a type of programmed cell death, 
results when two cells with incompatible geneotypes, het-s and het-S, fuse to form a mixed 
cytoplasm. The two alleles encode distinct sequence variants of the Het-s protein. One, 
HET-s, is able to form the [Het-s] prion, where as the other, HET-S, cannot adopt an 
amyloid conformation. The prion form of the HET-s allele by itself is completely benign. 
However, if the HET-S allele is expressed in the presence of the [Het-s] prion form it results 
in cell death. The interaction of HET-s protein with the [Het-s] prion form leads to the 
templated formation of additional non-toxic prion amyloid. On the other hand, we speculate 
that non-productive templating of the HET-S protein variant, which cannot form amyloid, 
by the [Het-s] prion form leads to the formation of a toxic misfolded species resulting in cell 
death (Fig. 2).
Conclusions
The protein deposits that are the hallmark of neurodegenerative diseases are now seen in a 
different light. Formerly viewed as the cause of cellular dysfunction and neuronal loss, 
especially intracellular protein deposits may be the product of a cellular process enabling 
cells to cope with the accumulation of misfolded and damaged proteins. This notion is 
supported by studies demonstrating that the deposition of damaged and misfolded proteins 
in inclusions enables mitotic cells, ranging from the unicellular organism Escherichia coli to 
human embryonic stem cells, to asymmetrically segregate the accumulated damage to the 
daughter cell with the shorter life expectancy.57,61–64 Based on our results in yeast, we 
suggest that inefficiencies in inclusion body and plaque formation, arising with 
accumulating protein damage, can result in the inception of toxic protein species due to non-
productive templating. Further studies are needed to elucidate which types of protein 
deposits in the individual diseases are protective, how their formation is controlled and how 
they circumvent the formation of more toxic species, such as prefibrillar oligomers.
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Aggregation of misfolded protein can give rise to oligomers, amorphous aggregates and 
inclusion bodies. The accumulation of misfolded protein leads to the formation of different 
protein assemblies. Prefibrillar oligomers formed by different proteins share a common 
structure and are thought to be the toxic protein species in diseases such as Alzheimer 
disease and Huntington disease.5,6 Oligomers are conformationally molten and can associate 
to form amorphous aggregates or convert to an amyloidogenic nucleus to initiate amyloid 
fibril formation. Amyloid fibrils have a highly organized structure due to repeating β-sheets 
and are insoluble. Amyloid fibrils are often found in intra- and extracellular inclusions such 
as inclusion bodies and amyloid plaques. The generation of amyloid fibers and inclusion 
bodies can protect cells by reducing the formation of highly interactive toxic oligomers and 
amorphous aggregates.
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Amyloid and Non-productive templating. Amyloid fibrils grow by causing proteins of the 
same amino-acid sequence to adopt the same amyloid conformation. This is referred to as 
amyloid templating and involves the efficient addition of monomers or oligomeric species to 
the amyloid fiber, which maybe assisted by specific chaperones (e.g., Rnq1 and the Hsp40 
Sis1, Sup35NM and Hsp104,49). If the amount of substrate exceeds the cellular capacity for 
amyloid conversion or if amino acid sequences are incompatible, the interaction of substrate 
with the amyloid fibrils may give rise to other abnormal conformational species, which may 
go on to form toxic oligomers and amorphous aggregates (Rnq1, PrP and Het-s/S). We refer 
to this as non-productive templating.
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